Re-evaluation of neohesperidine dihydrochalcone (E959) as a food additive.

Abstract

The present opinion deals with the re-evaluation of neohesperidine dihydrochalcone (E 959) when used as a food additive. It is obtained by catalytic hydrogenation of a flavanone - neohesperidine - which is naturally occurring and thus isolated by alcohol extraction in bitter oranges (Citrus aurantium). Based on invivo data in rat, neohesperidine dihydrochalcone is likely to be absorbed, also in humans, and to become systemically available. It does not raise a concern regarding genotoxicity. The toxicity data set consisted of studies on subchronic and prenatal developmental toxicity. No human studies were available. The data set was considered sufficient to derive a new acceptable daily intake (ADI). Based on the weight of evidence (WoE) analysis, the Panelconsidered unlikely that neohesperidine dihydrochalcone would lead to adverse effects on health in animals in the dose ranges tested. The Panelalso considered that a carcinogenicity study was not warranted and that the lack of human data did not affect the overall confidence in the body of evidence. The Panelderived an ADI of 20mg/kg bodyweight (bw) per day based on a no observed adverse effect level (NOAEL) of 4,000mg/kg bw per day from a 13-week study in rat, applying the standard default factors of 100 for inter- and intraspecies differences and of 2 for extrapolation from subchronic to chronic exposure. For the refined brand-loyal exposure assessment scenario, considered to be the most appropriate for the risk assessment, the exposure estimates at the mean ranged from < 0.01 to 0.09mg/kg bw per day and at the 95th percentile (P95) from 0.01 to 0.24mg/kg bw per day. Considering the derived ADI of 20mg/kg bw per day, the exposure estimates were below the reference value in all age groups. Therefore, the Panelconcluded that dietary exposure to the food additive neohesperidine dihydrochalcone (E959) at the reported uses and use levels would not raise a safety concern.